Avenue Therapeutics Q4 2023 Earnings Results & Report

Avenue Therapeutics EPS Results

• Actual EPS: $42.00
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Avenue Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Avenue Therapeutics (NASDAQ:ATXI) is a specialty pharmaceutical company focused on developing and commercializing therapies for acute and other serious medical conditions. The company is headquartered in the United States and trades on the Nasdaq under the symbol ATXI.

Avenue’s primary product candidate has been intravenous tramadol, an investigational formulation intended to provide short-term management of acute postoperative pain in adults who require an opioid analgesic in a medically supervised setting. The company has pursued regulatory approval in the United States and has conducted clinical and regulatory activities related to the product’s safety, efficacy and manufacturing.

Avenue Therapeutics was established as a subsidiary of Fortress Biotech, a biopharmaceutical company that supports the development of medicines through a subsidiary-based model. Its activities have primarily centered on advancing its lead acute-pain program through the U.S. regulatory process rather than operating a broad commercial product portfolio.